News | April 29, 2022
Ami Organics earmarks Rs 190 cr to expand API production in Ankleshwar
The plant is expected to start commercial operations from Q4FY24
The plant is expected to start commercial operations from Q4FY24
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Since its inception, the company has either acquired or taken a majority stake in five companies
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
She brings extensive expertise in managing global and domestic procurement operations
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Subscribe To Our Newsletter & Stay Updated
